2018 has witnessed concrete plans with the Polish Pol-Pharma, acting as the Pharmacare Marketing Authorisation Holder in Europe, to extend the exporting shipments of Taedalafil 2.5 mg 5 mg 10 mg and 20 mg to the UK, Denmark and Germany as part of the intended expansion scheme.